MedTrace Logo

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

NCT04354246 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2026-05-12

No results posted yet for this study

Summary

Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.

Conditions

Interventions

DRUG

Dose escalation: COM902 monotherapy.

COM902 monotherapy administered IV every 3 weeks in sequential dose escalation doses in cohorts of subjects.

COMBINATION_PRODUCT

Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)

Both study drugs will be evaluated at the RDFE for assessment of safety and tolerability. All study drugs will be administered IV every 3 weeks.

DRUG

Cohort expansion: COM902 (RDFE) monotherapy.

COM902 monotherapy (RDFE) in subjects with multiple myeloma. COM902 will be administered IV every 3 weeks.

DRUG

Cohort expansion: COM902 in combination with COM701 (both at the RDFE).

COM902 in combination with COM701 (both at RDFE) in subjects with select tumor types who have exhausted standard treatment - HNSCC, CRC (MSS), NSCLC. All study drugs will be administered IV every 3 weeks.

COMBINATION_PRODUCT

Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.

Triplet combination of COM902 + COM701 + Pembrolizumab administered IV every 3 weeks.

Sponsors & Collaborators

  • Compugen Ltd

    lead INDUSTRY

Principal Investigators

  • COM902 Study Director COM902 Study Director · Compugen Ltd

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-31
Primary Completion
2026-04-01
Completion
2026-04-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04354246 on ClinicalTrials.gov